Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
1(25%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
4
100%

Phase Distribution

4

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
4(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

4

all time

Status Distribution
Active(1)
Completed(3)

Detailed Status

Completed3
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
1
Success Rate
100.0%
Most Advanced
Phase 1

Trials by Phase

Phase 14 (100.0%)

Trials by Status

completed375%
active_not_recruiting125%

Recent Activity

1 active trials
Showing 4 of 4
active_not_recruitingphase_1

Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition

NCT02404688
completedphase_1

In Vivo Study of THC-induced Immune-genome Changes at Single Cell Solution in HIV-infected Humans

NCT04920539
completedphase_1

THC and Ketamine Effects in Humans: Relation to Neural Oscillations and Psychosis

NCT04199468
completedphase_1

Testing the Interactive Effects of Delta-9-Tetrahydrocannabinol and Pregnenolone

NCT02576912

Clinical Trials (4)

Showing 4 of 4 trials
NCT02404688Phase 1

Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition

Active Not Recruiting
NCT04920539Phase 1

In Vivo Study of THC-induced Immune-genome Changes at Single Cell Solution in HIV-infected Humans

Completed
NCT04199468Phase 1

THC and Ketamine Effects in Humans: Relation to Neural Oscillations and Psychosis

Completed
NCT02576912Phase 1

Testing the Interactive Effects of Delta-9-Tetrahydrocannabinol and Pregnenolone

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4